Xenetic biosciences, inc. and volitionrx limited collaborate to develop nets-targeted adoptive cell therapies for the treatment of cancer

Framingham, ma / accesswire / august 2, 2022 / xenetic biosciences, inc. (nasdaq:xbio) ("xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and volitionrx limited (nyse american:vnrx) ("volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop neutrophil extracellular traps ("nets") targeted, adoptive cell therapies for the treatment of cancer. the collaboration is an early exploratory program to evaluate the potential combination of volition's nu.q® nets test and xenetic's dnase-armored car t platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.
VNRX Ratings Summary
VNRX Quant Ranking